<SEC-DOCUMENT>0001558370-24-010370.txt : 20240730
<SEC-HEADER>0001558370-24-010370.hdr.sgml : 20240730
<ACCEPTANCE-DATETIME>20240730155522
ACCESSION NUMBER:		0001558370-24-010370
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240724
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240730
DATE AS OF CHANGE:		20240730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		241157198

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc-20240724x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 7/30/2024 6:40:36 PM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: e410b37b-d5af-4dce-91b5-35bec1a73fba -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://www.glycomimetics.com/20240724" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityCentralIndexKey" id="Tc_nPjiCZ3oLkWP7GNbsn1wQw_2_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:AmendmentFlag" id="Tc_RpS9snb25Uy2bInpXCjanw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="glyc-20240724.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-24</xbrli:startDate><xbrli:endDate>2024-07-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_936565da_6d49_4064_94b1_546727ccd46c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0pt;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:DocumentType" id="Narr_FrZKppDnDEi_hqrZ-OyWoQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_GoSPSHkln0-u1b5qBcZgbw"><b style="font-size:9pt;font-weight:bold;">July 24, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityRegistrantName" id="Narr_DpWin1v4gEqodD1u8CH9sw"><b style="font-weight:bold;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_e1f4de58_61bd_4709_b865_8049cd6378dd"></a><a id="Tc_GcXfNurHLkil79wjZt8aDA_2_0"></a><a id="Tc_5zkoi3xApUmZf6MxzqkuVw_2_2"></a><a id="Tc_DELHs6yB2E-UFd98G0Atew_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_K8i3q4c6ukGxKDHozF_Y3Q_1_0"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityFileNumber" id="Tc_t2PMnv807Uy3u7Et-D73PQ_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-36177</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityTaxIdentificationNumber" id="Tc_mbUu_2RedkGuCQ3HEzFh5A_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation)</p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer<br/>Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityAddressAddressLine1" id="Narr_zlgi1ia_EU6vcyK43kVZwA"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityAddressCityOrTown" id="Narr_CVC4yCrM0kaS0lmF89QeTg"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityAddressStateOrProvince" id="Narr_0_undtRqqU6g1NioQ2EGoA"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:EntityAddressPostalZipCode" id="Narr_heKubulYtkScRm5Fvvuoog"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices, including zip code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:CityAreaCode" id="Narr_KHl1DdG5JkiMnN2SLvptmg"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:LocalPhoneNumber" id="Narr_703Lmi8kgUKTdf-1m_6aUg"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_viOsIUr5AU6f9o_7XKdrUg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_vKAVLnxasE2HdPB9-WZXwg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_mAiR8tTlC0mvOlKwYSKMvw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_3cUy5DZb80CBPm1n87w1CA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_815aaab8_f3ad_460f_b7c2_43bd0f552b4c"></a><div style="margin-left:0pt;"><a id="Tc_VOkw0dmfb0Cp0gFTcVNOGQ_1_0"></a><a id="Tc_6xYJoTQKW02jhsNVNwTTPg_1_1"></a><a id="Tc_gwwUOeSMbEONyH3dlVnCMQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of each class</b></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:Security12bTitle" id="Tc_A_GyKFBRzU6NO8gmTfoZuA_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" name="dei:TradingSymbol" id="Tc_G7jXetmoLUmHEHDUjuO7dw_2_1"><span style="font-size:9pt;">GLYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_qgz8otKnwkmaNiOe1j4MNg_2_2"><span style="font-size:9pt;">The Nasdaq Stock Market</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Ind&#237;cate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_n8r_BR7H70-t3mjMz2JTDw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_778ee647_802a_4bda_b57e_de96edd3f167"></a><a id="_Hlk165888224"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.05.</b></span><b style="font-weight:bold;">Costs Associated with Exit or Disposal Activities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">The Board of Directors (the &#8220;<span style="font-style:italic;font-weight:bold;">Board</span>&#8221;) of GlycoMimetics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;) has approved a streamlined operating plan that includes the exploration of strategic alternatives focused on maximizing shareholder value. The Company has concluded, following feedback from the U.S. Food and Drug Administration, that the regulatory path forward for its lead product candidate uproleselan for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">In connection with the streamlined operating plan approved by the Board, on July 24, 2024, the authorized officers of the Company committed the Company to a corporate restructuring that includes a reduction in the Company&#8217;s workforce by 26 employees, or approximately 80% of its headcount. The Company expects to substantially complete the reduction by July 31, 2024. The Company anticipates recognizing approximately $3.6 million in total charges in connection with the headcount reduction, which costs are expected to be substantially recognized in the third quarter of 2024, <span style="background:#ffffff;">with related cash payments expected to be paid out by the end of 2024</span>. &#160;These charges will consist primarily of <span style="background:#ffffff;">one-time&#160;severance payments upon termination and continued benefits for a specified period of time</span>. <span style="background:#ffffff;">The Company expects such costs to be the only direct expense of the workforce reduction; however, t</span>he charges the Company expects to incur are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 5.02. </b></span><b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">As part of the reduction in force described in Item 2.05 above, the employment of Dr. Edwin Rock, the Company&#8217;s Chief Medical Officer, will end on July 31, 2024 (the &#8220;<span style="font-style:italic;font-weight:bold;">Separation Date</span>&#8221;). &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">The Company expects to enter into a Separation Agreement with Dr. Rock, which will be effective as of the Separation Date. Under the Separation Agreement, subject to Dr. Rock executing a general release of claims in the Company&#8217;s favor, the Company will pay Dr. Rock, as severance, the equivalent of twelve (12) months of his base salary in effect as of the Separation Date, subject to standard payroll deductions and withholdings. &#160;This amount will be paid in a lump sum on the Company&#8217;s next regular payroll date following the Separation Date, provided that Dr. Rock has signed and not revoked the Separation Agreement as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">In addition, the Company will also pay the federal COBRA (or, if applicable, state continuation coverage) premiums to continue healthcare coverage for Dr. Rock and his covered dependents, as applicable, for twelve (12) months from the Separation Date or, if earlier, the date when he becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment or the date on which he ceases to be eligible for COBRA or state continuation coverage for any reason (such period, the &#8220;<span style="font-style:italic;font-weight:bold;">COBRA Payment Period</span>&#8221;). &#160;If the Company determines that its payment of the COBRA premiums on Dr. Rock&#8217;s behalf would violate applicable law, then the Company will pay Dr. Rock each month during the COBRA Payment Period a cash payment equal to the COBRA premium for such month, subject to applicable tax withholding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">The Company expects to enter into a separate agreement with Dr. Rock (the &#8220;<span style="font-style:italic;font-weight:bold;">Consulting Agreement</span>&#8221;), to be effective as of the Separation Date, pursuant to which Dr. Rock will, at the request of the Company&#8217;s President and Chief Executive Officer, or his designee, provide the Company with consulting services through January 31, 2025 (the &#8220;<span style="font-style:italic;font-weight:bold;">Consulting Period</span>&#8221;). During the Consulting Period, Dr. Rock will be paid a specified hourly rate, subject to obtaining advance approval from an authorized representative of the Company to provide such consulting services. &#160;Dr. Rock&#8217;s provision of services under the Consulting Agreement will constitute &#8220;Continuous Service&#8221; for purposes of continued vesting and exercising of his outstanding equity awards under the Company&#8217;s equity incentive plans. &#160; &#160; &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">The foregoing descriptions of the Separation Agreement and Consulting Agreement are qualified in their entirety by reference to the full text of such agreements. &#160;Copies of the Separation Agreement and the Consulting Agreement, if executed, will be filed as exhibits to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:67.3pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;7.01</b></span><b style="font-weight:bold;">Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:5pt;text-align:justify;text-indent:31.7pt;background:#ffffff;margin:5pt 0pt 0pt 0pt;">On July 25, 2024, the Company issued a press release related to the corporate restructuring and its plan to conduct a strategic review of its business. This press release is attached as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.7pt;background:#ffffff;margin:0pt 0pt 5pt 0pt;">The information provided in this Item 7.01 of this Current Report on Form&#160;8-K,&#160;including Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Securities Act</span>&#8221;) or the Exchange Act, except as expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:9pt;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:14pt 0pt 0pt 0pt;">Statements contained in this report regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company&#8217;s streamlined operating plan, the expected costs of the reduction in force and the timing of recognition of such charges. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the risks inherent in the clinical and regulatory development of pharmaceutical products, and the risks described more fully in the Company&#8217;s filings with the Securities and Exchange Commission, including the &#8220;Risk Factors&#8221; section of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2024. All forward-looking statements contained in this report speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>(d) Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.3%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9,</p></div></div></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:88.1%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.3%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"/><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:88.1%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"/></tr><tr><td style="vertical-align:bottom;width:10.3%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:88.1%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:88.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.3%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:88.1%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20240724xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release, dated July 25, 2024, &#8220;GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan.&#8221;</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.3%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:88.1%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:normal;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><a id="_1e992bfd_2943_4957_94c5_dd6d1d689c6a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0pt;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;"><span style="letter-spacing:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></div></div></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GLYCOMIMETICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">By:&#160;&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Date:  July 30, 2024</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian M. Hahn<br/>Senior Vice President and Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glyc-20240724xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 7/30/2024 06:40:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><img src="glyc-20240724xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:34.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:160pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan </b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">After meeting with the U.S Food and Drug Administration (FDA), it has been determined that the regulatory path forward for uproleselan in relapsed and refractory (R/R) Acute Myeloid Leukemia (AML) would require an additional clinical trial </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company will conduct a strategic review of the business seeking to maximize shareholder value, including the evaluation of potential business development opportunities for uproleselan and GMI-1687 to ensure their continued advancement</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company is advancing discussions with the National Cancer Institute (NCI) and Alliance for Clinical Trials in Oncology for the ongoing Phase 2/3 study of uproleselan in newly diagnosed AML patients </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company will reduce its workforce by approximately 80%; cash and cash equivalents are expected to fund the company into the second quarter of 2025</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;line-height:1.37;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;">ROCKVILLE, Md.<font style="background:#ffffff;">--(BUSINESS WIRE)--July 25, 2024--&#160;</font>GlycoMimetics, Inc.<font style="background:#ffffff;">&#160;(Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="background:#ffffff;">&#8220;We are committed to acting in the best interests of patients, employees and shareholders. Given our organization&#8217;s cash resources, we plan to explore a range of potential strategic alternatives and seek to deliver value to our shareholders and find avenues that allow uproleselan and GMI-1687 to build upon their clinical promise, including in the ongoing NCI Phase 2/3 study of uproleselan in newly diagnosed AML patients,&#8221; said Harout Semerjian, Chief Executive Officer of GlycoMimetics. &#8220;We believe both drug candidates have the potential to address significant unmet needs in their respective therapeutic areas and we are focused on finding organizations to advance these programs. We are proud of our team&#8217;s dedication to improving the lives of patients and are thankful for their hard work progressing uproleselan and GMI-1687.&#8221; &#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="background:#ffffff;">The Company will evaluate strategic alternatives that include, but are not limited to, an acquisition, company sale, merger, business combination, asset sale, joint venture, licensing arrangement, or other transaction.</font> No timetable has been set for the conclusion of the strategic review or the consummation of any such strategic transaction.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="background:#ffffff;">GlycoMimetics had cash and cash equivalents of approximately $31.3 million as of March 31, 2024. Based on the corporate restructuring and streamlining of operations, the Company expects to </font>significantly reduce future operating expenses and extend its cash runway into the second quarter of 2025.<font style="background:#ffffff;"> </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><img src="glyc-20240724xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:34.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:160pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">NCI Phase 2/3 Study of Uproleselan in Frontline AML</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology are conducting an adaptive Phase 2/3 study of uproleselan in adults with newly diagnosed AML who are 60 years or older and fit for intensive chemotherapy. Their randomized, controlled study is evaluating the addition of uproleselan to a standard cytarabine / daunorubicin regimen (7+3) versus chemotherapy alone. The Phase 2 portion of the study completed enrollment of 267 patients in December 2021. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About AML</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">AML is the most common acute leukemia in adults. A cancer of the bone marrow, nearly 21,000 people in&#160;the United States&#160;are diagnosed with AML each year. Despite the availability of multiple treatments, disease prognosis is poor, and new treatment options are needed to improve outcomes. Newly diagnosed AML has the lowest 5-year survival rate of all leukemias at 31.7%. The five-year survival rate for people with relapsed/refractory disease is only 10%.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About Uproleselan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Discovered and developed by&#160;GlycoMimetics, uproleselan (yoo&#8217; pro le&#8217;se lan) is an investigational, first-in-class E-selectin antagonist.&#160;GlycoMimetics&#160;has received Breakthrough Therapy and Fast Track designations from the&#160;U.S. Food and Drug Administration&#160;(FDA) and Breakthrough Therapy designation from the&#160;Chinese National Medical Products Administration&#160;for uproleselan as a potential treatment for adult AML patients with relapsed or refractory disease. E-selectin is a leukocyte adhesion molecule constitutively expressed on endothelial cells of the vasculature and bone marrow. In AML, there is evidence that E-selectin&#8211;ligand interaction between endothelial cells in the protective niche of the Bone Marrow microEnvironment (BME) and leukemic stem cells and blasts promotes leukemic cell survival and hides them from AML therapies. Uproleselan is designed to disrupt E-selectin binding and prevent leukemic myeloid cells using the protective niche of the BME.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About GMI-1687</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Discovered and developed by&#160;GlycoMimetics, GMI-1687 is a highly potent E-selectin antagonist that is bioavailable after subcutaneous administration. This second-generation compound has potential application in oncology and inflammatory diseases, and the company&#8217;s initial clinical development has focused on sickle-cell disease (SCD). E-selectin is believed to play a major role in vaso-occlusive events (VOEs), a group of acute complications that are associated with SCD and include vaso-occlusive pain crises, acute chest syndrome (ACS), stroke, and splenic sequestration.&#160;Administration of GMI-1687&#160;by subcutaneous injection, if successfully developed in the clinic, may enable this study drug to be approved as a patient-controlled, point-of-care treatment option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><img src="glyc-20240724xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:34.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:160pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About&#160;GlycoMimetics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">GlycoMimetics&#160;is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company&#8217;s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation.&#160; </font><font style="font-family:'Calibri','Helvetica','sans-serif';">The company&#8217;s goal is to develop transformative therapies for diseases with high unmet medical need.&#160;GlycoMimetics&#160;is headquartered in&#160;Rockville, MD&#160;in the&#160;BioHealth Capital Region. Learn more at&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">www.glycomimetics.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of a strategic review of its business, the implementation of a corporate restructuring plan, the extension of its cash resources, and the potential benefits and impact of its product candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&#160;GlycoMimetics, please see the risk factors described in the company&#8217;s Annual Report on Form 10-K filed with the&#160;U.S. Securities and Exchange Commission&#160;(SEC) on&#160;March 27, 2024, the company&#8217;s Quarterly Report on Form 10-Q filed with the&#160;SEC&#160;on&#160;May 9, 2024, and other filings&#160;GlycoMimetics&#160;makes with the&#160;SEC&#160;from time to time. Forward-looking statements speak only as of the date of this release, and&#160;GlycoMimetics&#160;undertakes no obligation to update or revise these statements, except as may be required by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;line-height:1.19;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;background:#ffffff;margin:0pt 0pt 21pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Investor Contact:</b><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Argot Partners</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Leo Vartorella</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">212-600-1902</font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Glycomimetics@argotpartners.com</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>glyc-20240724xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20240724xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !% 4 # 2(  A$! Q$!_\0
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M$VVTRV\3:9'JUMIM['J-M#,QV+.F=CD \XR>#QS7444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>glyc-20240724.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/30/2024 6:40:41 PM-->
<!--Modified on: 7/30/2024 6:40:41 PM-->
<xsd:schema targetNamespace="http://www.glycomimetics.com/20240724" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:glyc="http://www.glycomimetics.com/20240724" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20240724_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20240724_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>glyc-20240724_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/30/2024 6:40:41 PM-->
<!--Modified on: 7/30/2024 6:40:41 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20240724.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>glyc-20240724_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/30/2024 6:40:41 PM-->
<!--Modified on: 7/30/2024 6:40:41 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20240724.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20240724.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638579616412867086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638579616412867086" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638579616412867086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638579616412867086" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638579616412867086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638579616412867086" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638579616412867086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638579616412867086" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638579616412867086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638579616412867086" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638579616412867086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638579616412867086" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638579616412867086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638579616412867086" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638579616412877089" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638579616412877089" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638579616412877089" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638579616412877089" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638579616412877089" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638579616412877089" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638579616412877089" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638579616412877089" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638579616412877089" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638579616412877089" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638579616412877089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638579616412877089" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638579616412887085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638579616412887085" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638579616412887085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638579616412887085" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638579616412887085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638579616412887085" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638579616412887085" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638579616412887085" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140152714964048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 24,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M9V 3[@7X?:F4?6^X$V[Y#XK1OU!+ P04    " #J?OY8GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( .I^_E@<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L)
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #J?OY8!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M .I^_E@8J)J:[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( .I^_EB97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ZG[^6'A+
M@A-*!   K!   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( .I^_EB?H!OPL0(  .(,   -
M  "  8X,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ZG[^6)>*NQS
M$P(   L              ( !:@\  %]R96QS+RYR96QS4$L! A0#%     @
MZG[^6!PX9>H_ 0  / (   \              ( !4Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( .I^_E@D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .I^
M_EAED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glyc-20240724x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>glyc-20240724.xsd</File>
    <File>glyc-20240724_lab.xml</File>
    <File>glyc-20240724_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="glyc-20240724x8k.htm">glyc-20240724x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "glyc-20240724x8k.htm": {
   "nsprefix": "glyc",
   "nsuri": "http://www.glycomimetics.com/20240724",
   "dts": {
    "schema": {
     "local": [
      "glyc-20240724.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20240724_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20240724_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "glyc-20240724x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20240724x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20240724x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.glycomimetics.com/20240724",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-24-010370-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-010370-xbrl.zip
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M'NTV12.=X)HDVTEK2W7]'5!+ P04    " #J?OY8GC!TQ8$%  !-/   %0
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MC^(V%(;O*_4_N.EUOH#A2S.[8MC9"G7803-4N^K-RB0&K"9V9)L!_GWM$+-
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M<M1>?Q[%=C2'O+K#O7WZ>)9ZJ,_>S1O>/=STX5]02P,$%     @ ZG[^6,3
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MW,:'XGK?..@0)P>44EJ4_4'%)^QWD;X4GIY([-%4JA)+V+&87>9QS"A TS_
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M"N[7G%6LX:XX5=("A>7D\"JCK>.?+X+/W:=--HBA)Y1M8%C0OZ?^-\% :ZV
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M$)E6 J#_WD/8( !Y2E24/ )>&*BXU_-^;UN\E$&W>JJO=_38?)90S!D9-%+
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M-]COBCFTE^.8@8NK/JWAHP'*V""^P([Q1&7&!^#SMCCWH3F&&BK.)BVNB@*
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M  !G;'EC+3(P,C0P-S(T>#AK+FAT;5!+ 0(4 Q0    ( .I^_EA3&$O8R!$
M &U<   8              "  4@N  !G;'EC+3(P,C0P-S(T>&5X.3ED,2YH
8=&U02P4&      4 !0!- 0  1D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>glyc-20240724x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20240724.xsd" xlink:type="simple"/>
    <context id="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2024-07-24</startDate>
            <endDate>2024-07-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_nPjiCZ3oLkWP7GNbsn1wQw_2_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_RpS9snb25Uy2bInpXCjanw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_FrZKppDnDEi_hqrZ-OyWoQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_GoSPSHkln0-u1b5qBcZgbw">2024-07-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_DpWin1v4gEqodD1u8CH9sw">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_K8i3q4c6ukGxKDHozF_Y3Q_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_t2PMnv807Uy3u7Et-D73PQ_1_2">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_mbUu_2RedkGuCQ3HEzFh5A_1_4">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_zlgi1ia_EU6vcyK43kVZwA">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_CVC4yCrM0kaS0lmF89QeTg">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_0_undtRqqU6g1NioQ2EGoA">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_heKubulYtkScRm5Fvvuoog">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_KHl1DdG5JkiMnN2SLvptmg">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_703Lmi8kgUKTdf-1m_6aUg">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_viOsIUr5AU6f9o_7XKdrUg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_vKAVLnxasE2HdPB9-WZXwg">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_mAiR8tTlC0mvOlKwYSKMvw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_3cUy5DZb80CBPm1n87w1CA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_A_GyKFBRzU6NO8gmTfoZuA_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_G7jXetmoLUmHEHDUjuO7dw_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Tc_qgz8otKnwkmaNiOe1j4MNg_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_24_2024_To_7_24_2024_9CfcaZzq1kW5s6VsUpwOlQ"
      id="Narr_n8r_BR7H70-t3mjMz2JTDw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
